摘要
目的:探讨新辅助化疗对非小细胞肺癌患者肿瘤标志物与细胞凋亡相关因子的影响。方法:本研究以2019年3月-2020年12月在泉州市第一医院治疗的95例中晚期非小细胞肺癌患者为研究对象。按照随机数字表法分为对照组(47例)和试验组(48例)。对照组患者直接行手术治疗,然后给予常规化疗,试验组患者在术前采取新辅助化疗,化疗结束后30 d行手术治疗及术后常规化疗。比较两组患者治疗结束后6个月临床效果;比较两组患者治疗前、治疗结束后3个月血清肿瘤标志物[癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)]和细胞凋亡相关因子[凋亡因子B淋巴细胞瘤基因-2(Bcl-2)、Bcl-2相关X蛋白(Bax)、可溶性凋亡相关因子(sFas)和可溶性Fas配体(sFasL)]水平。结果:治疗后随访6个月,对照组患者临床总有效率为61.70%,试验组为81.25%,两组临床总有效率比较,差异有统计学意义(P<0.05)。治疗后3个月,试验组和对照组患者血清CEA、CYFRA21-1和CA125均低于治疗前(P<0.05),试验组患者血清CEA、CYFRA21-1和CA125均低于对照组(P<0.05)。治疗后3个月,试验组和对照组患者血清Bcl-2均下降,Bax、sFas、sFasL均升高,且试验组均优于对照组(P<0.05)。结论:新辅助化疗治疗非小细胞肺癌患者临床效果显著,可显著降低患者血清肿瘤标志物水平,促进癌细胞凋亡。
Objective: To investigate the effect of neoadjuvant chemotherapy on tumor markers and apoptosis-related factors in patients with non-small cell lung cancer. Method: This study included 95 patients with advanced non-small cell lung cancer treated in the First Hospital of Quanzhou City from March 2019 to December 2020. According to random number table method, they were divided into control group(47 cases) and experimental group(48 cases). The control group received direct surgical treatment and then conventional chemotherapy, and the experimental group received neoadjuvant chemotherapy before surgery, 30 days after chemotherapy, received surgical treatment and then conventional chemotherapy. The clinical effects of the two groups were compared 6months after treatment;the levels of serum tumor markers [carcinoembryonic antigen(CEA), cytokeratin 19 fragment antigen 21-1(CYFRA21-1) and carbohydrate antigen 125(CA125)] and apoptosis related factors [apoptosis factor B lymphoma gene-2(Bcl-2), Bcl-2 related X(Bax), soluble apoptosis related factors(sFas) and soluble Fas ligand(sFasL)] were compared between the two groups before treatment and 3 months after treatment. Result: Follow up for 6 months after treatment, the total clinical effective rate was 61.70% in the control group and 81.25% in the experimental group, the total clinical effective rate between the two groups was statistically significant(P<0.05).Three months after treatment, the serum CEA, CYFRA21-1 and CA125 in the experimental group and the control group were lower than those before treatment(P<0.05), and the serum CEA, CYFRA21-1 and CA125 in the experimental group were lower than those in the control group(P<0.05). At 3 months after treatment, serum Bcl-2decreased and Bax, sFas and sFasL increased in experimental group and control group, and those of experimental group were better than those of the control group(P<0.05). Conclusion: Neoadjuvant chemotherapy has a significant clinical effect in the treatment of patients with non-small cell lung cancer, wh
作者
林洪盛
刘利敏
鲁秋香
吴清
LIN Hongsheng;LIU Limin;LU Qiuxiang;WU Qing(The First Hospital of Quanzhou City,Fujian Province,Quanzhou 362000,China;不详)
出处
《中国医学创新》
CAS
2023年第3期45-49,共5页
Medical Innovation of China
关键词
新辅助化疗
非小细胞肺癌
肿瘤标志物
细胞凋亡
Neoadjuvant chemotherapy
Non-small cell lung cancer
Tumor markers
Apoptosis
